Business Context and Reporting Period
TG Therapeutics, Inc. (TGTX) filed a Current Report on Form 8-K dated March 18, 2026. The filing reports the entry into a material definitive agreement regarding the amendment of its existing financing structure.
Key Financial Metrics and Debt Structure
The company established a new $750 million term loan facility (the "2026 Term Loan"), which was borrowed in full on the closing date. Proceeds were used to repay the Initial Term Loans in full. Additionally, an uncommitted additional facility of up to $250 million was established.
- Principal Amount: $750 million (Term Loan) + up to $250 million (Uncommitted Facility).
- Maturity Date: March 18, 2031.
- Interest Rate: Applicable margin plus Base Rate or Term SOFR (minimum 1.00%).
- Pricing Grid: Commences at 4.75% for SOFR borrowings and 3.75% for Base Rate borrowings, with a 25 basis point step-down upon achieving specific leverage thresholds.
- Amortization: Quarterly payments of $37.5 million commence with the fiscal quarter ending March 31, 2030. Payments may be deferred to maturity if leverage thresholds are met.
- Collateral: Secured by a lien on substantially all assets of the Borrower and certain subsidiaries.
The filing text does not provide clear values for revenue, profit, cash flow, or operating margins as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the refinancing of the company's debt obligations. The Initial Term Loans were fully repaid and replaced by the 2026 Term Loan, extending the maturity date to 2031 and establishing a new interest rate structure tied to the Total Net Leverage Ratio.
Outlook, Risks, and Contingencies
The agreement contains customary covenants and representations. Events of default are standard for this financing type; if triggered, the Administrative Agent may accelerate amounts due. The interest rate is variable and dependent on the company's Total Net Leverage Ratio, introducing interest expense volatility based on future financial performance.
Investor Verification Checklist
- Verify the exact Total Net Leverage Ratio thresholds required to achieve the 25 basis point interest rate step-down.
- Confirm the specific definition of "Initial Term Loans" being repaid to assess the net cash impact.
- Review the full text of the First Amendment (to be filed as an exhibit to the Q1 2026 Form 10-Q) for detailed covenant restrictions.
- Monitor the company's ability to meet the leverage thresholds required to defer amortization payments starting in 2030.